Reason for request

Inclusion on the list of medicines approved for hospital use in the extension of the indication to the treatment of atypical haemolytic uremic syndrome (aHUS).


Clinical Benefit


The actual benefit of SOLIRIS 300 mg, concentrate for solution for infusion, is substantial in this indication.

Clinical Added Value


SOLIRIS 300 mg, an orphan medicine, provides an important improvement in actual benefit (IAB II) compared to standard treatment for patients with aHUS.

Contact Us

Évaluation des médicaments

See also